Skip NavigationSkip to Content
Return Return to Search Results

Challenge of Chimpanzees Immunized With a Recombinant Canarypox-Hiv-1 Virus

  1. Author:
    Girard, M.
    Vanderryst, E.
    Barresinoussi, F.
    Nara, P.
    Tartaglia, J.
    Paoletti, E.
    Blondeau, C.
    Jennings, M.
    Verrier, F.
    Meignier, B.
    Fultz, P. N.

  2. Author Address

    Blondeau C INST PASTEUR UNITE VIROL MOL 25 RUE DR ROUX F-75724 PARIS FRANCE INST PASTEUR F-75015 PARIS FRANCE NCI FREDERICK, MD 20892 USA VIROGENET CORP TROY, NY 12180 USA PARTEUR MERIEUX CONNAUGHT MARCY LETOILE FRANCE NYU MED CTR LAB EXPT SURG PRIMATES NEW YORK, NY 10016 USA UNIV ALABAMA SCH MED BIRMINGHAM, AL 35487 USA UFS DEPT VIROL BLOEMFONTEIN SOUTH AFRICA
    1. Year: 1997
  2. Journal: Virology
    1. 232
    2. 1
    3. Pages: 98-104
  4. Type of Article: Article
  1. Abstract:

    To evaluate the potential protective efficacy of a live recombinant human immunodeficiency virus type 1 (HIV-1) canarypox vaccine candidate, two chimpanzees were immunized five times with ALVAC-HIV-1 vCP250, a recombinant canarypox virus that expresses the HIV-I-IIIB(LAI) gp120/TM, gag, and protease gene products. One month after the last booster inoculation, the animals were challenged by intravenous injection of cell-associated virus in the form of peripheral blood mononuclear cells from an HIV-1(IIIB(LAI))-infected chimpanzee. One chimpanzee with a neutralizing antibody titer to HIV-1(IIIB(LAI)) of 128 at the time of challenge was protected, whereas both the second animal, with a neutralizing antibody titer of 32, and a naive control animal became infected. At 5 months after challenge, the protected chimpanzee and a third animal, previously immunized with various HIV-1(MN) antigens, were given a booster inoculation. The two animals were challenged intravenously 5 weeks later with twenty 50% tissue culture infectious doses of cell-free HIV-1(DH12), a heterologous subtype a isolate. Neither chimpanzee had neutralizing antibodies to HIV-1(DH12), and neither one was protected from infection with this isolate. The immune responses elicited by vaccination against HIV-1(IIIB(LAI)) or HIV-1(MN) did not, therefore, protect the animals from challenge with the heterologous cell-free HIV-1(DH12). (C) 1997 Academic Press. [References: 39]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel